Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT
Phase 2 Placebo-Controlled, Single-Site, Single-Blind Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT
Sponsor: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Listed as NCT03172910, this PHASE2 trial focuses on Healthy and remains completed. Sponsored by Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc., it has been updated 11 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Oct 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Oct 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Oct 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Jun 2020 — Oct 2020 [monthly]
Recruiting PHASE2
-
Dec 2018 — Jun 2020 [monthly]
Recruiting PHASE2
-
Sep 2018 — Dec 2018 [monthly]
Recruiting PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE2
-
Jun 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
May 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .